Arctic Bioscience - Regulatory Filings 2026

Arctic Bioscience invited to present at the Glaucoma 360 New Horizons Forum

Arctic Bioscience are pleased to announce that we have been invited to present

at the Glaucoma 360 New Horizons Forum in San Francisco on January 30th 2026, in

the session 'The Perfect Dose: Innovating Drugs and Drug Delivery'.

Our Medical Director, Runhild Gammelsæter, will be presenting our latest

pipeline project, ABS403, with the aim to promote resolution of inflammation and

support neuroprotection in glaucoma. This eye disease does not currently have a

cure and leads to blindness.

The project was initiated based on encouraging clinical signals from a pilot

study in glaucoma (POAG).

As we prepare for the next stages, we are actively seeking partners and

investors to join us in advancing ABS403 into further clinical development.

Read more about the event: https://glaucoma360.org/

Read more about the promising pilot trial by Luo et al:

https://doi.org/10.1007/s10792-025-03693-1

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.

AI assistant